Literature DB >> 23360454

Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy.

Régis T Costello1, Anne Boehrer, Carole Sanchez, Delphine Mercier, Céline Baier, Thérèse Le Treut, Gérard Sébahoun.   

Abstract

In monoclonal gammopathies (MG) and multiple myeloma (MM), normal natural cytotoxicity receptors (NCR) expression (NCR1/NKp46, NCR2/NKp44, NCR3/NKp30) is observed in natural killer (NK) cells. Nonetheless, except in plasma cell leukemia, few tumor plasmocytes are present in PB, while NK studies have been performed on peripheral blood (PB). For this reason we focused our attention on NK from bone marrow (BM). Our study demonstrates that the down-regulation of NCR3/NKp30 is only detectable in NK from BM but not in PB, and shows a drastic decrease of both NKG2D and CD244/2B4/p38 expression in NK from BM in comparison with PB. In conclusion, our data more precisely describe the mechanism of immune escape of MG/MM from innate immunity since we show a drastic down regulation of 3 major activating NK receptors (NCR3/NKp30, NKG2D and CD244/2B4/p38) at the site of tumor, i.e BM, that was undetectable in PB. Further studies regarding immune regulatory drugs in MG/MM will imperiously require the assessment of immune cell status not only in PB but also in BM to obtain more relevant data regarding anti-tumor efficacy.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23360454      PMCID: PMC3701180          DOI: 10.1111/imm.12082

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  9 in total

1.  Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma.

Authors:  C Fauriat; F Mallet; D Olive; R T Costello
Journal:  Leukemia       Date:  2006-04       Impact factor: 11.528

2.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

3.  Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked.

Authors:  Marie von Lilienfeld-Toal; Susanne Frank; Christiane Leyendecker; Sylvia Feyler; Sarah Jarmin; Ruth Morgan; Axel Glasmacher; Angela Märten; Ingo G H Schmidt-Wolf; Peter Brossart; Gordon Cook
Journal:  Cancer Immunol Immunother       Date:  2009-12-19       Impact factor: 6.968

Review 4.  Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.

Authors:  C J Sanchez; T Le Treut; A Boehrer; B Knoblauch; J Imbert; D Olive; R T Costello
Journal:  Cancer Immunol Immunother       Date:  2010-08-10       Impact factor: 6.968

5.  CD48 as a novel molecular target for antibody therapy in multiple myeloma.

Authors:  Naoki Hosen; Hiroyoshi Ichihara; Atsuko Mugitani; Yasutaka Aoyama; Yuki Fukuda; Satoshi Kishida; Yoshikazu Matsuoka; Hiroko Nakajima; Manabu Kawakami; Tamotsu Yamagami; Shigeo Fuji; Hiroya Tamaki; Takafumi Nakao; Sumiyuki Nishida; Akihiro Tsuboi; Shinsuke Iida; Masayuki Hino; Yoshihiro Oka; Yusuke Oji; Haruo Sugiyama
Journal:  Br J Haematol       Date:  2011-11-21       Impact factor: 6.998

Review 6.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

7.  HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.

Authors:  Ennio Carbone; Paola Neri; Maria Mesuraca; Mariateresa T Fulciniti; Takemi Otsuki; Daniela Pende; Veronika Groh; Thomas Spies; Giuditta Pollio; David Cosman; Lucio Catalano; Pierfrancesco Tassone; Bruno Rotoli; Salvatore Venuta
Journal:  Blood       Date:  2004-08-24       Impact factor: 22.113

8.  NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G.

Authors:  G Maki; G M Hayes; A Naji; T Tyler; E D Carosella; N Rouas-Freiss; S A Gregory
Journal:  Leukemia       Date:  2008-02-21       Impact factor: 11.528

9.  Defining early human NK cell developmental stages in primary and secondary lymphoid tissues.

Authors:  Diana N Eissens; Jan Spanholtz; Arnold van der Meer; Bram van Cranenbroek; Harry Dolstra; Jaap Kwekkeboom; Frank W M B Preijers; Irma Joosten
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

  9 in total
  29 in total

Review 1.  Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.

Authors:  Sabarinath Venniyil Radhakrishnan; Neelam Bhardwaj; Tim Luetkens; Djordje Atanackovic
Journal:  Oncoimmunology       Date:  2017-03-28       Impact factor: 8.110

Review 2.  Multiple solitary plasmacytoma with multifocal bone involvement. First clinical case report in a uraemic patient.

Authors:  Pietro Dattolo; Marco Allinovi; Stefano Michelassi; Francesco Pizzarelli
Journal:  BMJ Case Rep       Date:  2013-05-23

3.  Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.

Authors:  G Venton; Y Labiad; J Colle; A Fino; S Afridi; M Torres; S Monteuil; B Loriod; N Fernandez-Nunez; L Farnault; P Suchon; J C Mattei; P Rihet; A Bergon; C Nguyen; C Baier; R Costello
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

4.  Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.

Authors:  Hua Jiang; Wenhao Zhang; Peipei Shang; Hui Zhang; Weijun Fu; Fei Ye; Tianmei Zeng; Hejing Huang; Xueguang Zhang; Wanping Sun; Daniel Man-Yuen Sze; Qing Yi; Jian Hou
Journal:  Mol Oncol       Date:  2013-12-12       Impact factor: 6.603

5.  Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.

Authors:  Nina Shah; Li Li; Jessica McCarty; Indreshpal Kaur; Eric Yvon; Hila Shaim; Muharrem Muftuoglu; Enli Liu; Robert Z Orlowski; Laurence Cooper; Dean Lee; Simrit Parmar; Kai Cao; Catherine Sobieiski; Rima Saliba; Chitra Hosing; Sairah Ahmed; Yago Nieto; Qaiser Bashir; Krina Patel; Catherine Bollard; Muzaffar Qazilbash; Richard Champlin; Katy Rezvani; Elizabeth J Shpall
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

6.  The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.

Authors:  Tatiana Pazina; Ashley M James; Alexander W MacFarlane; Natalie A Bezman; Karla A Henning; Christine Bee; Robert F Graziano; Michael D Robbins; Adam D Cohen; Kerry S Campbell
Journal:  Oncoimmunology       Date:  2017-06-16       Impact factor: 8.110

7.  Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression.

Authors:  Tehila Azoulay; Ilana Slouzky; Michal Karmona; Margarita Filatov; Michal Hayun; Yishai Ofran; Galit Sarig; Shimrit Ringelstein-Harlev
Journal:  Cancer Immunol Immunother       Date:  2022-09-01       Impact factor: 6.630

8.  Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts.

Authors:  Régis T Costello; Amélie Leclercq; Thérèse Le Treut; Carole Sanchez; Delphine Mercier; Gérard Sébahoun
Journal:  Leuk Res Rep       Date:  2015-01-15

9.  Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21.

Authors:  Jaya Lakshmi Thangaraj; Minh-Trang Thi Phan; SoonHo Kweon; Jinho Kim; Jong-Min Lee; Ilwoong Hwang; Jeehun Park; Junsang Doh; Seung-Hwan Lee; Manh-Cuong Vo; Tan-Huy Chu; Ga-Young Song; Seo-Yeon Ahn; Sung-Hoon Jung; Hyeoung-Joon Kim; Duck Cho; Je-Jung Lee
Journal:  Cancer Immunol Immunother       Date:  2021-07-20       Impact factor: 6.968

Review 10.  MiRNAs and lncRNAs in NK cell biology and NK/T-cell lymphoma.

Authors:  FengXia Gao; SiRong He; AiShun Jin
Journal:  Genes Dis       Date:  2020-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.